Valsartan

Diovan treats hypertension in adults and children age ≥1. It reduces heart-failure hospitalization in adults with NYHA II–IV heart failure and cardiovascular mortality in clinically stable adults with LV failure/dysfunction after MI. Prexxartan hypertension starts at age 6; its heart-failure/post-MI indications are for patients unable to swallow valsartan tablets. Valsartan has no demonstrated added HF benefit with an adequate ACE-inhibitor dose, and combined RAS blockade is generally avoided.

Diovan tablet: start 80 or 160 mg once daily in non-volume-depleted adults, range 80–320 mg once daily. Prexxartan 4 mg/mL solution: start 40 or 80 mg TWICE daily (10 or 20 mL each dose), total range 80–320 mg/day. Blood-pressure effect is substantially present in two weeks and maximal around four; adjust to response or add appropriate therapy.

For HF, both labels start 40 mg twice daily and titrate toward 80 then 160 mg twice daily as tolerated; consider reducing concomitant diuretic. Post-MI treatment may start as early as 12 hours in clinically stable eligible patients at 20 mg twice daily, reach 40 mg twice daily within seven days, then target 160 mg twice daily as tolerated. Reduce if symptomatic hypotension/renal dysfunction. Prexxartan is restricted to patients unable to swallow tablets for these indications; specialist-directed monitoring is essential.

Use the actual product’s pediatric regimen and confirm both mg and mL with an oral dosing device.

Diovan’s labeled pharmacy-prepared 4 mg/mL SUSPENSION has about 60% higher AUC than tablets; they are not substitutable mg-for-mg and should not be combined to make a total dose. The pharmacist’s exact preparation uses eight 80-mg Diovan tablets in a final 160 mL of the specified Ora-Plus/Ora-Sweet SF vehicles. Shake at least ten seconds before dispensing/use under the preparation instructions. Prexxartan is a ready-made 4 mg/mL SOLUTION, not that suspension; compared with tablets it has 86% higher peak and 25% higher AUC and is not therapeutically equivalent. A prescriber must specify conversions and follow its own dose instructions; equal liquid concentration does not establish interchangeability.

Take the missed dose when remembered unless nearly time for the next; do not double. Mild/moderate adult renal impairment and mild/moderate liver disease require no labeled adjustment; severe disease lacks established dosing/evidence. Pediatric dialysis or GFR <30 mL/min/1.73 m² lacks data. Correct volume depletion and review blood pressure, creatinine and potassium before titration.

Both labels formally contraindicate hypersensitivity to a component and aliskiren coadministration in patients with diabetes. Pregnancy has a boxed fetal-toxicity stop instruction; do not confuse that with the formal section 4 list. In general avoid other RAS inhibitors; severe organ disease calls for assessment rather than an invented automatic dose.

Both products carry a fetal-toxicity boxed warning: discontinue valsartan as soon as possible when pregnancy is detected. Drugs acting directly on the RAS can cause fetal injury and death. Discuss pregnancy plans before prescribing.

Dizziness, hypotension, fatigue, abdominal/GI symptoms and potassium/creatinine changes are reported; HF patients commonly experience blood-pressure effects. Rare spontaneous reports include angioedema, kidney failure, liver injury and bullous dermatitis, with uncertain rates. Overdose may produce profound hypotension, tachycardia or bradycardia, depressed consciousness or shock; immediate medical assessment/support is required. Hemodialysis does not remove valsartan.

Generally avoid ACE inhibitors, other ARBs or aliskiren combinations because hypotension, hyperkalemia and kidney injury increase without usual added benefit. Aliskiren is contraindicated with diabetes and avoided with GFR <60. Do not add valsartan to Entresto: it already contains an ARB. Entresto’s 36-hour washout applies when switching to/from an ACE inhibitor, not as a blanket washout rule for valsartan monotherapy; the prescriber must coordinate the specific transition.

Potassium supplements/salt substitutes, potassium-sparing diuretics, heparin and other potassium-raising drugs need monitoring. NSAIDs can blunt the BP effect and cause renal deterioration, particularly with older age, dehydration or renal disease. Lithium concentrations/toxicity can increase: monitor levels. In vitro OATP1B1/MRP2 inhibitor findings suggest rifampin, cyclosporine or ritonavir may increase valsartan exposure; reconcile without inventing a fixed dose adjustment.

Discontinue promptly for pregnancy; fetal renal impairment, oligohydramnios, lung/skull abnormalities, neonatal hypotension, renal failure and death can follow later-pregnancy exposure. Discuss replacement treatment and fetal/neonatal assessment as appropriate. Both labels advise against breastfeeding during treatment because infant effects and milk presence are insufficiently established and serious renal-development effects are possible; animal milk findings do not prove human safety.

Diovan hypertension is labeled from age 1; its dose table covers 1–16. Prexxartan hypertension is labeled from age 6, with doses studied through 16. Below the respective ages, use is not recommended; no pediatric HF/post-MI regimen is supplied. Monitor pediatric creatinine/potassium particularly with underlying renal abnormalities. Older patients need no purely age-based adjustment but may be more vulnerable with dehydration or kidney disease.

Mild (GFR 60–90) or moderate (30–60) renal impairment requires no labeled dose change; safety/effectiveness in GFR <30 is not established, and pediatric dialysis/severe renal impairment lacks data. Mild/moderate liver disease needs no labeled adjustment, although exposure is increased; no severe-liver-disease recommendation is supplied. Monitor response and renal/potassium changes rather than assuming absent adjustment means absent risk.

Valsartan blocks angiotensin II at AT1 receptors, reducing vasoconstriction and aldosterone-related effects. It does not inhibit ACE/bradykinin degradation; this does not eliminate possible angioedema. Most antihypertensive effect develops within two weeks and maximal response around four.

Diovan tablets peak around two to four hours; valsartan is about 95% protein bound and has an elimination half-life around six hours. Recovery is mainly unchanged drug in feces and urine, with limited metabolism. Diovan tablet bioavailability is about 25%; its suspension and Prexxartan solution have different exposure increases, so neither a common ingredient nor 4-mg/mL concentration establishes equivalence. Food changes exposure; follow the exact product’s instructions.

Assess BP and symptoms during initiation/titration, with periodic creatinine/renal and potassium checks especially with HF, CKD, pediatric renal disease, diuretics or NSAIDs. Review faintness, fluid losses and new medicines; lithium requires level monitoring if combined. No universal fixed test schedule is supplied by these labels.

Report pregnancy immediately, avoid breastfeeding during therapy, and consult before potassium salt substitutes or NSAIDs. Report lightheadedness; if fainting occurs, withhold until the clinician is consulted under label instructions. Severe facial/throat swelling or breathing trouble needs emergency care. Verify tablet/liquid name, concentration, mg and mL, use a calibrated oral device, follow shaking directions for suspension and do not double missed doses.

Diovan 40 mg is a yellow ovaloid functionally scored tablet marked “NVR” and “DO,” bottle of 30 NDC 0078-0423-15; it supports a labeled 20-mg post-MI dose. Other tablet strengths have multiple label-described shapes. Prexxartan is a clear colorless grape-flavored 4-mg/mL solution; current AptaPharma 120-mL bottle NDC 76281-0155-64. Appearance and packaging depend on manufacturer.

Diovan tablets: 40, 80, 160 and 320 mg. Its label specifies a pharmacy-prepared 4-mg/mL oral suspension, not a factory bottled Diovan solution. Prexxartan is commercial 4 mg/mL solution in 120-/473-mL bottles and 20-mL unit-dose cups. Neither is automatically interchangeable with tablets or with each other. Single-agent valsartan is distinct from valsartan/HCTZ and sacubitril/valsartan.

Diovan tablets: 20–25°C, excursions 15–30°C, protect from moisture and dispense tightly closed. Pharmacy-prepared Diovan suspension uses the specified amber glass bottle and child-resistant closure: up to 30 days below 30°C OR up to 75 days refrigerated at 2–8°C, following pharmacy preparation instructions. Shake well at least ten seconds. Prexxartan: 20–25°C, excursions 15–30°C; tight container. Do not copy suspension storage duration or preparation to the commercial solution.